LAVA Therapeutics (NASDAQ:LVTX) Short Interest Update

LAVA Therapeutics (NASDAQ:LVTX) saw a significant decrease in short interest in the month of November. As of November 30th, there was short interest totalling 21,100 shares, a decrease of 20.1% from the November 15th total of 26,400 shares. Based on an average daily volume of 61,100 shares, the days-to-cover ratio is currently 0.3 days. Approximately 0.2% of the company’s stock are short sold.

LAVA Therapeutics Trading Down 7.5 %

Shares of LVTX stock traded down $0.09 during trading on Friday, hitting $1.11. The company’s stock had a trading volume of 157,486 shares, compared to its average volume of 528,124. The company has a market cap of $28.14 million, a PE ratio of -1.08 and a beta of 0.43. The business has a fifty day moving average of $1.69 and a 200-day moving average of $1.83. LAVA Therapeutics has a 52 week low of $1.08 and a 52 week high of $6.47.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. Leerink Partners reiterated a “market perform” rating and set a $2.00 price objective (down from $11.00) on shares of LAVA Therapeutics in a report on Thursday. Citizens Jmp downgraded LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday. Leerink Partnrs downgraded LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday. Finally, JMP Securities reaffirmed a “market perform” rating and set a $6.00 target price on shares of LAVA Therapeutics in a research report on Wednesday. Four investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat, LAVA Therapeutics currently has an average rating of “Hold” and an average target price of $4.67.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of LVTX. Pathway Financial Advisors LLC boosted its holdings in shares of LAVA Therapeutics by 328.6% in the 2nd quarter. Pathway Financial Advisors LLC now owns 60,000 shares of the company’s stock worth $108,000 after buying an additional 46,000 shares during the last quarter. XTX Topco Ltd purchased a new position in LAVA Therapeutics in the second quarter valued at about $55,000. Finally, Virtu Financial LLC bought a new position in shares of LAVA Therapeutics during the 3rd quarter valued at approximately $32,000.

LAVA Therapeutics Company Profile

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.